This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH PLAINFIELD, N.J.,
Feb. 25, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of
Guido Schopen, M.D. to General Manager and Head of Medical Affairs for
Europe. Dr. Schopen will be responsible for European commercial operations, reporting to
Mark Rothera, Chief Commercial Officer of PTC.
"We are delighted to welcome Dr. Schopen to our team where he will play a key leadership role in building out our European commercial capabilities," stated Mr. Rothera. "PTC is expanding its commercial footprint with a near term focus on certain pre-approval activities. Our ultimate goal is to build a specialty global commercial organization to bring ataluren to Duchenne muscular dystrophy and cystic fibrosis patients as soon as possible following regulatory approvals. Dr. Schopen's medical and commercial expertise will be instrumental in achieving this goal."
Prior to joining PTC, Dr. Schopen was Vice President, Global Commercial Operations and Medical Affairs for TiGenix NV, where he oversaw both the commercialization of the first approved cell therapy product for cartilage repair in
Europe (ChondroCelect®) and the clinical development strategy of the company's adult stem cell programs. Dr. Schopen has more than 20 years of experience in the industry with leadership positions in sales, marketing, business development, life-cycle management, clinical development and general management at ICI Pharma, UCB Pharma, Bayer HealthCare and Behringwerke. He received his undergraduate and medical degrees from the University of RWTH Aachen,
"I am pleased to join PTC at this exciting time in the company's evolution. Ataluren is a novel product candidate with significant potential across multiple genetic disorders," stated Dr. Schopen. "PTC's unrelenting commitment to bring this potentially disease modifying therapy to patients suffering from rare disorders is impressive and I look forward to being part of that effort."